

## DAFTAR PUSTAKA

- Abd El-Lateef, A. E. *et al.* (2022) 'Coagulation Profile in COVID-19 Patients and its Relation to Disease Severity and Overall Survival: A Single-Center Study', *British Journal of Biomedical Science*, 79(April), pp. 1–9. doi: 10.3389/bjbs.2022.10098.
- Abu-Farha, M. *et al.* (2020) 'Prognostic Genetic Markers for Thrombosis in COVID-19 Patients: A Focused Analysis on D-Dimer, Homocysteine and Thromboembolism', *Frontiers in Pharmacology*, 11.
- Al Otair, H., AlSaleh, K., AlQahtany, F. S., Al Ayed, K., Al Ammar, H., Al Mefgai, N., & Al Zeer, F. (2021). 'The Level of vWF Antigen and Coagulation Markers in Hospitalized Patients with Covid-19', *Journal of blood medicine*, 12, 809–817. <https://doi.org/10.2147/JBM.S318940>
- Asteris, P.G., Gavriilaki, E., Touloumenidou, T., Koravou, E.E., Koutra, M. *et al.* (2022) 'Genetic prediction of ICU hospitalization and mortality in COVID-19 patients using artificial neural networks', *J Cell Mol Med*, 26(5), 1445-1455. doi: 10.1111/jcmm.17098.
- Bautista-Vargas, M., Bonilla-Abadía, F. and Cañas, C. A. (2020) 'Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19', *Journal of Thrombosis and Thrombolysis*. Springer US, 50(3), pp. 479–483. doi: 10.1007/s11239-020-02172-x.
- Bayrakci, N., Ozkan, G., Mutlu, L. C., Erdem, L., Yildirim, I., Gulen, D., & Celikkol, A. (2021). Relationship between serum soluble endothelial protein C receptor level and COVID-19 findings. *Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis*, 32(8), 550–555. <https://doi.org/10.1097/MBC.0000000000001070>
- Bibha R, V.K. Sharma. (2017). Transcriptome profiling: methods and applications- A review. *Agricultural Reviews*. doi: 10.18805/ag.R-1549

Bounds, JE and Kok, SJ (2023) 'D Dimer' StatPearls Publishing LLC.  
<https://www.ncbi.nlm.nih.gov/books/NBK431064/>.

Burhan, E. *et al.* (2020) *Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020, Pedoman Tatalaksana COVID-19.* Available at:  
<https://www.papdi.or.id/download/983-pedoman-tatalaksana-covid-19-edisi-3-desember-2020>.

Burke, R. M. *et al.* (2020) 'Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020', *MMWR. Morbidity and Mortality Weekly Report*, 69(9), pp. 245–246. doi: 10.15585/mmwr.mm6909e1.

CDC (2020) 'Summary of Guidance Review', pp. 1–8. Available at:  
<https://www.cdc.gov/coronavirus/2019-ncov/downloads/communication/Guidance-Review.pdf>.

Ceballos, F.C., Ryan, P., Blancas, R., Martin-Vicente, M., Vidal-Alcántara, E.J. *et al.* (2021) 'Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality?', *Front Med (Lausanne)*, 8, 718053. doi: 10.3389/fmed.2021.718053. PMID: 34660629; PMCID: PMC8514618.

Chaudhry, R., Usama, S. M. and Babiker, H. M. (2021) *Physiology, Coagulation Pathways, StatPearl.* Stat Pearl Publishing.

Colucci, G. and Tsakiris, D. A. (2020) 'Thrombophilia screening revisited: an issue of personalized medicine', *Journal of Thrombosis and Thrombolysis*.

Conway, EM (2012) 'Thrombomodulin and its role in inflammation' *Semin Immunopathol* 2012 Jan;34(1):107-25. doi: 10.1007/s00281-011-0282-8.

Costanzo, M., Caterino, M., Fedele, R., Cevenini, A., Pontillo, M., Barra, L., & Ruoppolo, M. (2022). COVIDomics: The Proteomic and Metabolomic Signatures of COVID-19. *International journal of molecular sciences*, 23(5), 2414. <https://doi.org/10.3390/ijms23052414>

- Crooks, M. G., & Hart, S. P. (2015). Coagulation and anticoagulation in idiopathic pulmonary fibrosis. *European respiratory review : an official journal of the European Respiratory Society*, 24(137), 392–399. <https://doi.org/10.1183/16000617.00008414>
- Cui, S. *et al.* (2020) ‘Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia’, *Journal of Thrombosis and Haemostasis*, 18(6), pp. 1421–1424. doi: 10.1111/jth.14830.
- Demichev, V.; Tober-Lau, P.; Lemke, O.; Nazarenko, T.; Thibeault, C.; Whitwell, H.; Röhl, A.; Freiwald, A.; Szyrwiel, L.; Ludwig, D.; et al. (2021). A time-resolved proteomic and prognostic map of COVID-19. *Cell Syst.* 12, 780–794.e7. [CrossRef]
- Di Gennaro, F. *et al.* (2020) ‘Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review’, *International Journal of Environmental Research and Public Health*. 17(8). doi:10.3390/ijerph17082690.
- Doremalen, N. van *et al.* (2020) ‘Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1’, *Nejm*, pp. 0–2.
- Dos Santos Silva B, Jara C, Sidarta-Oliveira D, Velloso L, Velander W, P Araujo E. (2022). Hypercoagulability in COVID-19 and its putative association with the downregulation of protein C signalling [abstract]. *The International Society on Thrombosis and Haemostasis*.
- Duz, M. E., Balçı, A., & Menekşe, E. (2020). ‘D-dimer levels and COVID-19 severity: Systematic Review and Meta-Analysis’, *Tuberkuloz ve toraks*, 68(4), 353–360. <https://doi.org/10.5578/tt.70351>.
- Ellery, PER, *et al.*, (2018) ‘Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S’ *Res Pract Thromb Haemost*, 2018 Jan;2(1):93-104. doi: 10.1002/rth2.12058. Epub 2017 Dec 29.

- Englert, H. *et al.* (2021) 'Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation', *EBioMedicine*. Elsevier, 67. doi: 10.1016/J.EBIOM.2021.103382.
- FitzGerald, E. S., Chen, Y., Fitzgerald, K. A., & Jamieson, A. M. (2021). 'Lung Epithelial Cell Transcriptional Regulation as a Factor in COVID-19-associated Coagulopathies', *American journal of respiratory cell and molecular biology*, 64(6), 687–697. <https://doi.org/10.1165/rcmb.2020-0453OC>
- FitzGerald, E. S., Jamieson, A. M. (2020). 'Unique transcriptional changes in coagulation cascade genes in SARS-CoV-2-infected lung epithelial cells: A potential factor in COVID-19 coagulopathies', *bioRxiv : the preprint server for biology*, 2020.07.06.182972. <https://doi.org/10.1101/2020.07.06.182972>
- Francischetti, I. M. B., Toomer, K., Zhang, Y., Jani, J., Siddiqui, Z. *et al.* (2021). 'Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection', *EClinicalMedicine*, 39, 101069. <https://doi.org/10.1016/j.eclinm.2021.101069>
- Fricke-Galindo, I. and Falfán-Valencia, R. (2021) 'Genetics Insight for COVID-19 Susceptibility and Severity: A Review', *Frontiers in Immunology*, 12, p. 622176. doi:10.3389/fimmu.2021.622176.
- García, M. M. A. *et al.* (2021) 'Mechanisms of infection by SARS-CoV-2, inflammation and potential links with the microbiome', *Future Virology*, 16(1), pp. 43–57. doi: 10.2217/fvl-2020-0310. [bin/carddisp.pl?gene=PLAUR&keywords=PLAUR](https://doi.org/10.2217/fvl-2020-0310).
- Girard, T. J., Antunes, L., Zhang, N., Amrute, J. M., Subramanian, R. *et al.* (2022). 'Peripheral blood mononuclear cell tissue factor (F3 gene) transcript levels and circulating extracellular vesicles are elevated in severe coronavirus 2019 (COVID-19) disease', *Journal of thrombosis and haemostasis : JTH*, S1538-7836(22)07649-8. Advance online publication. <https://doi.org/10.1016/j.jtha.2022.11.033>

- Giri, H., Cai, X., Panicker, S. R., Biswas, I., & Rezaie, A. R. (2019). Thrombomodulin Regulation of Mitogen-Activated Protein Kinases. *International journal of molecular sciences*, 20(8), 1851. <https://doi.org/10.3390/ijms20081851>
- Gando, S., & Wada, T. (2021). Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. *Frontiers in immunology*, 12, 649122. <https://doi.org/10.3389/fimmu.2021.649122>
- [Griffin](#), JH, [Lyden](#), P (2020) 'COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation' *Res Pract Thromb Haemost*. 2020 Jun 12;4(4):506-509. doi: 10.1002/rth2.12362.
- Gupta, R.K. *et al.* (2021) 'Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium', *PLOS ONE*. Edited by E. Ito, 16(9), p. e0257784. doi:10.1371/journal.pone.0257784.
- Han, H., Yang, L., Liu, R., Liu, F., Wu, K. L., Li, J., Liu, X. H., & Zhu, C. L. (2020). 'Prominent changes in blood coagulation of patients with SARS-CoV-2 infection', *Clinical chemistry and laboratory medicine*, 58(7), 1116–1120. <https://doi.org/10.1515/cclm-2020-0188>.
- Hayıroğlu, M. İ., Çınar, T., & Tekkeşin, A. İ. (2020). 'Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review', *Revista da Associacao Medica Brasileira (1992)*, 66(6), 842–848. <https://doi.org/10.1590/1806-9282.66.6.842>.
- Helms, J. *et al.* (2020) 'High risk of thrombosis in patients with severe SARS- CoV-2 infection: a multicenter prospective cohort study', *Intensive Care Medicine*. Springer Berlin Heidelberg, 46(6), pp. 1089–1098. doi:10.1007/s00134-020-06062-x.

- Henry, B. M. *et al.* (2020) ‘Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis’, *Clinica Chimica Acta*, 507(January), pp. 167–173. doi:10.1016/j.cca.2020.04.027.
- Iba, T. and Levy, J. H. (2022) ‘Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination’, *Trends in Cardiovascular Medicine*. Elsevier Inc., (xxxx). doi: 10.1016/j.tcm.2022.02.008.
- Ibañez, C., Perdomo, J., Calvo, A., Ferrando, C., Reverter, J. C., Tassies, D., & Blasi, A. (2021). ‘High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there?’, *Journal of thrombosis and thrombolysis*, 51(2), 308–312. <https://doi.org/10.1007/s11239-020-02226-0>.
- [Jackson](#), SP, [Darbousset](#), R , [Schoenwaelder](#), SM (2019) ‘Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms’ *Blood*. 2019, Feb 28;133(9):906-918. doi: 10.1182/blood-2018-11-882993.
- Jha, P. K., Vijay, A., Halu, A., Uchida, S., & Aikawa, M. (2021). ‘Gene Expression Profiling Reveals the Shared and Distinct Transcriptional Signatures in Human Lung Epithelial Cells Infected With SARS-CoV-2, MERS-CoV, or SARS-CoV: Potential Implications in Cardiovascular Complications of COVID-19’, *Frontiers in cardiovascular medicine*, 7, 623012. <https://doi.org/10.3389/fcvm.2020.623012>
- Johnson, E. D., Schell, J. C. and Rodgers, G. M. (2019) ‘The D-dimer assay’, *American Journal of Hematology*. John Wiley & Sons, Ltd, 94(7), pp. 833–839. doi: <https://doi.org/10.1002/ajh.25482>.
- Joly, B. S., Siguret, V. and Veyradier, A. (2020) ‘Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19’, *Intensive Care Medicine*. Springer Berlin Heidelberg, 46(8), pp. 1603–1606. doi:10.1007/s00134-020-06088-1.

Kathleen E, Brummel Z, Thomas O, Stephen J, Everse, Kenneth G, Mann. (2017). Blood Coagulation and Fibrinolysis. Wintrob. *Clinical Hematology*, 14<sup>th</sup> Edition. pp. 1418-1603.

[Kaushansky](#), K, *et al.*, (2021) ‘*Williams Hematology, 10e Eds*’ McGraw-Hill Education, 2021, McGraw Hill Professional, 14 Jan 2021: 2528 halaman. [https://books.google.co.id/books/about/Williams\\_Hematology\\_10th\\_Edition.html?id=xmT5DwAAQBAJ&redir\\_esc=y](https://books.google.co.id/books/about/Williams_Hematology_10th_Edition.html?id=xmT5DwAAQBAJ&redir_esc=y)

Klok, F. A. *et al.* (2020) ‘Thrombotic complications in critically ill patients with COVID 19’, *Thrombosis research*, 191(January), pp. 56. doi: 10.1016/j.thromres.2020.04.032.

Kollias, A. *et al.* (2020) ‘Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action’, *British Journal of Haematology*, 189(5), pp. 846–847. doi: 10.1111/bjh.16727.

Kragholm, K., Andersen, M.P., A Gerds, T., Butt, J.H., Østergaard L., *et al.* (2021). ‘Association Between Male Sex and Outcomes of Coronavirus Disease 2019 (COVID-19)-A Danish Nationwide, Register-based Study’, *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 73, pp. e4025–e4030. doi: 10.1093/cid/ciaa924.

Kwaan, H. C., & Lindholm, P. F. (2021). ‘The Central Role of Fibrinolytic Response in COVID-19-A Hematologist's Perspective’, *International journal of molecular sciences*, 22(3), 1283. <https://doi.org/10.3390/ijms22031283>

Lam, W, Moosavi, L (2023) ‘Physiology, Factor V’ StatPearls Publishing; Treasure Island, FL, USA: 2022. <https://pubmed.ncbi.nlm.nih.gov/31334957/>

[Lee](#), WJ, [Kim](#), YJ, and [Lee](#), HD (2022) ‘South Korean validation of the COVID-related-PTSD scale in a non-clinical sample exposed to the COVID-19 pandemic’ *BMC Psychol.* 2022; 10: 135. doi: [10.1186/s40359-022-00844-2](https://doi.org/10.1186/s40359-022-00844-2).

Lemke, G., Silverman, G.J. (2020). Blood clots and TAM receptor signalling in COVID-19 pathogenesis. *Nat Rev Immunol* 20, 395–396 <https://doi.org/10.1038/s41577-020-0354-x>

- Levi, M., & van der Poll, T. (2017). Coagulation and sepsis. *Thrombosis research*, 149, 38–44. <https://doi.org/10.1016/j.thromres.2016.11.007>
- Li, J. *et al.* (2020) ‘D-Dimer as a Prognostic Indicator in Critically Ill Patients Hospitalized With COVID-19 in Leishenshan Hospital, Wuhan, China’, *Frontiers in Pharmacology*, 11.
- [Lippi](#), G , Henry, BM, [Favaloro](#), EJ (2021) ‘Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients’ *Clin Chem Lab Med* 2021 Jun 14;59(11):e413-e415. doi: 10.1515/cclm-2021-0561.
- Lio, D. *et al.* (2021) ‘SARS CoV2 infection\_The longevity study perspectives’, *Ageing Research Reviews*, 67, p. 101299. doi:10.1016/j.arr.2021.101299.
- Lodigiani, C. *et al.* (2020) ‘Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy’, *Thrombosis Research*. Elsevier, 191, pp. 9–14. doi: 10.1016/j.thromres.2020.04.024.
- Mackman N., Antoniak S., Wolberg A.S., Kasthuri R., Key N.S. (2020). ‘Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses’, *Arterioscler Thromb Vasc Biol*. 2020;40:2033–2044.
- Mao, L. *et al.* (2020) ‘Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China’, *JAMA Neurology*, 77(6), pp. 683–690. doi: 10.1001/jamaneurol.2020.1127.
- Marietta, M. *et al.* (2020) ‘COVID-19 and haemostasis: A position paper from Italian Society on Thrombosis and Haemostasis (SISST)’, *Blood Transfusion*, 18(3), pp. 167–169. doi: 10.2450/2020.0083-20.
- Martín-Rojas, R. M., Pérez-Rus, G., Delgado-Pinos, V. E., Domingo-González, A., Regalado-Artamendi, I. *et al.* (2020). ‘COVID-19 coagulopathy: An in-depth analysis of the coagulation system’, *European journal of haematology*, 105(6), 741–750. <https://doi.org/10.1111/ejh.13501>



- Martos, L., Ramón, L. A., Oto, J., Fernández-Pardo, Á., Bonanad, S. et al. (2018). 'α2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:α2M Levels Are Associated with Venous Thromboembolism', *Thrombosis and haemostasis*, 118(4), 630–638. <https://doi.org/10.1055/s-0038-1629902>
- Mast, A. E., Wolberg, A. S., Gailani, D., Garvin, M. R., Alvarez, C., Miller, J. I., Aronow, B., & Jacobson, D. (2021). 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung', *eLife*, 10, e64330. <https://doi.org/10.7554/eLife.64330>.
- Mazurkiewicz-Pisarek, A. et al. (2016) 'The factor VIII protein and its function', *Acta Biochimica Polonica*, 63(1), pp. 11–16. doi: 10.18388/abp.2015\_1056.
- Mei, Z. W., van Wijk, X. M. R., Pham, H. P., and Marin, M. J. (2021) 'Role of von Willebrand Factor in COVID-19 Associated Coagulopathy', *J. Appl. Lab. Med.* 6, 1305–1315. doi:10.1093/jalm/jfab042
- Miles LA, Ny L, Wilczynska M, Shen Y, Ny T, Parmer RJ. (2021) Plasminogen Receptors and Fibrinolysis, *Int J Mol Sci.* 22(4), pp. 1712. doi: 10.3390/ijms22041712.
- Mukhopadhyay S, Johnson TA, Duru N, Buzza MS, Pawar NR, Sarkar R, Antalis TM. (2019) Fibrinolysis and Inflammation in Venous Thrombus Resolution. *Front Immunol.*10, pp. 1348. doi: 10.3389/fimmu.2019.01348.
- Munir MA, Kuganda H, Basry A. (2020). The Efficacy and Safety of Antivirus Drugs for COVID-19: A Systematic Review. 11(7): 162-166.
- Murray, N. P., Guzman, E. and del Prado, M. (2021) 'Transient acquired factor XII deficiency associated with moderately severe Covid-19 pneumonia', *Hematology, Transfusion and Cell Therapy.* Sociedade Brasileira de Hematologia e Hemoterapia, 43(4), p. 515. doi: 10.1016/J.HTCT.2021.06.017.

Nahum, J. et al. (2020) 'Venous Thrombosis among Critically Ill Patients with Coronavirus Disease 2019 (COVID-19)', *JAMA Network Open*, 3(5), pp. 2020–2023. doi: 10.1001/jamanetworkopen.2020.10478.

Nekrasova, L. A., Shmakova, A. A., Samokhodskaya, L. M., Kirillova, K. I., Stoyanova, S. S. et al. (2022). 'The Association of *PLAUR* Genotype and Soluble suPAR Serum Level with COVID-19-Related Lung Damage Severity', *International journal of molecular sciences*, 23(24), 16210. <https://doi.org/10.3390/ijms232416210>

[Nickel](#) et al., (2017) 'Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases' *Arterioscler Thromb Vasc Biol*, 2017 Jan;37(1):13-20. doi: 10.1161/ATVBAHA.116.308595. Epub 2016 Nov 10.

O'Donnell JS, O'Sullivan JM, Preston RJS. (2019) Advances in understanding the molecular mechanisms that maintain normal haemostasis. *Br J Haematol*, 186(1), pp. 24-36. doi: 10.1111/bjh.15872.

OMIM (2020a) *ALPHA-2-MACROGLOBULIN; A2M*. Available at: <https://www.omim.org/entry/103950?search=ALPHA-2-MACROGLOBULIN&highlight=%22alpha%22%22alpha%7Cmacroglobulin%22%28alpha2macroglobulin%7C%29alpha2macroglobulin>.

OMIM (2022). *COAGULATION FACTOR XII; F12* <https://omim.org/entry/610619?search=hageman&highlight=hageman>

OMIM (2022) *Thrombomodulin*.

OMIM (2022d) *Coagulation Factor V; F5 Factor V Leiden*. Available at: <https://www.omim.org/entry/612309?search=Factor V&highlight=factor v>.

OMIM (2022f) *EPCR; PROTEIN C RECEPTOR; PROCRCR*. Available at: <https://www.omim.org/entry/600646?search=EPCR&highlight=ePCR>.

OMIM (2022g) *Factor III*. Available at:

<https://www.omim.org/entry/134390?search=F3&highlight=f3>.

OMIM (2022h) *FXIII , A1 SUBUNIT; F13A1*. Available at:  
<https://www.omim.org/entry/134570?search=FXIII&highlight=fxiii>.

OMIM (2022k) *OMIM*.

OMIM (2022n) *Plasminogen activator receptor urokinase-type; PLAUR*. Available at:  
[https://www.omim.org/entry/173391?search=plasminogen acativator urokinase&highlight=acativator plasminogen urokinase](https://www.omim.org/entry/173391?search=plasminogen+acativator+urokinase&highlight=acativator+plasminogen+urokinase).

OMIM (2022o) 'PROTEIN S; PROS1 PROTEIN S PSEUDOGENE'. Available at:  
<https://www.omim.org/entry/176880?search=PROS1&highlight=pros1>.

OMIM (2022q) *Serpin Peptidase Inhibitor, Clade E (Nexin, Plasminogen Activator Inhibitor Type 1), PAI-1*. doi: 10.1007/978-3-319-67199-4\_103472.

OMIM (2022u) *Von Willebrand Factor*.

Overmyer, K. A., Shishkova, E., Miller, I. J., Balnis, J., Bernstein, M. N. *et al.* (2020). 'Large-scale Multi-omic Analysis of COVID-19 Severity', *medRxiv : the preprint server for health sciences*, 2020.07.17.20156513.  
<https://doi.org/10.1101/2020.07.17.20156513>.

Panigada, M., Bottino, N., Tagliabue, P., Grasselli, G., Novembrino, C. *et al.* (2020). 'Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis', *Journal of thrombosis and haemostasis : JTH*, 18(7), 1738–1742.  
<https://doi.org/10.1111/jth.14850>

PDPI (2020) 'Pneumonia COVID-19 Diagnosis dan Penatalaksanaan': Perhimpuna Dokter Paru Indonesia. Jakarta, 2020.

Rabaan, A. A. *et al.* (2021) 'Role of inflammatory cytokines in covid-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm', *Vaccines*, 9(5). doi: 10.3390/vaccines9050436.

- Rabi, F. A. *et al.* (2020) 'Sars-cov-2 and coronavirus disease 2019: What we know so far', *Pathogens*, 9(3), pp. 1–14. doi: 10.3390/pathogens9030231.
- Raffield, L. M. *et al.* (2017) 'D-Dimer in African Americans', *Arteriosclerosis, Thrombosis, and Vascular Biology*. American Heart Association, 37(11), pp. 2220–2227. doi: 10.1161/ATVBAHA.117.310073.
- Rathore, P. K. *et al.* (2020) 'Coagulation Factors: An Overview Studies on Components of Blood & Their Functions', *Openaccessebooks.Com*, 1(6), pp. 1–12. Available at: [www.openaccessebooks.com](http://www.openaccessebooks.com).
- Seitz, R., Gürtler, L., Schramm, W. (2021) 'Thromboinflammation in COVID-19: Can  $\alpha 2$ -macroglobulin help to control the fire?', *J Thromb Haemost*, 19(2), 351-354. doi: 10.1111/jth.15190. Epub 2020 Dec 19. PMID: 33230947; PMCID: PMC7753444.
- Shi, Y., Yu, X., Zhao, H., Wang, H., Zhao, R., Sheng, J., (2020). 'Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan', *Crit Care*, 24(1), pp. 108. doi: 10.1186/s13054-020-2833-7.
- Stanne, T. M., Pedersen, A., Gisslén, M., & Jern, C. (2021). 'Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19', *Thrombosis research*, 204, 13–15. <https://doi.org/10.1016/j.thromres.2021.05.016>
- Stavrov, and Schmaier (2010) 'Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis' *Thromb Res*, 2010 Mar;125(3):210-5. doi:10.1016/j.thromres.2009.11.028.
- Stefely, J. A., Christensen, B. B., Gogakos, T., Cone Sullivan, J. K., Montgomery, G. G., Barranco, J. P., & Van Cott, E. M. (2020). 'Marked factor V activity elevation in severe COVID-19 is associated with venous

thromboembolism', *American journal of hematology*, 95(12), 1522–1530.  
<https://doi.org/10.1002/ajh.25979>.

Stoichitoiu, L. E., Pinte, L., Balea, M. I., Nedelcu, V., Badea, C., & Baicus, C. (2020). 'Anticoagulant protein S in COVID-19: low activity, and associated with outcome', *Romanian journal of internal medicine = Revue roumaine de medecine interne*, 58(4), 251–258. <https://doi.org/10.2478/rjim-2020-0024>

Sugiyama, M. *et al.* (2021) 'Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19', *Gene*, 766, p. 145145. doi:10.1016/j.gene.2020.145145.

Tang *et al.* (2020) 'Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia', *Journal of Thrombosis and Haemostasis*, 18(4), pp. 844–847. doi: 10.1111/jth.14768.

Trevisan, C., Noale, M., Prinelli, F., Maggi, S., Sojic, A., *et al.* (2021). 'Age-Related Changes in Clinical Presentation of Covid-19: the EPICOVID19 Web-Based Survey', *Eur J Intern Med*, 86, pp. 41-47. doi: 10.1016/j.ejim.2021.01.028

UniProt (2022) 'COAGULATION FACTOR'.

UniProt (2022aa) *Tissue Factor - P13726 ( TF \_ HUMAN ) Protein Tissue factor.*  
Available at: [https://www.uniprot.org/uniprot/P13726#names\\_and\\_taxonomy](https://www.uniprot.org/uniprot/P13726#names_and_taxonomy).

UniProt (2022ab) 'Urokinase plasminogen activator surface receptor ( UPAR \_ HUMAN )'. Available at: <https://www.uniprot.org/uniprot/Q03405>.

UniProt (2022ac) *Von Willebrand Factor.*

UniProt (2022c) 'Alpha-2-Macroglobulin - P1023 (A2MG\_HUMAN)'. Available at:  
<https://www.uniprot.org/uniprot/P01023>.

UniProt (2022i) *F5 - P12259 Protein Coagulation factor V.* Available at:  
<https://www.uniprot.org/uniprot/P12259>.

UniProt (2022m) *FXIII.* Available at: <https://www.uniprot.org/uniprot/P00488>.

UniProt (2022n) ‘Kallikrein\_P06870 (KLK1\_HUMAN)’, 06870. Available at:  
<https://www.uniprot.org/uniprot/P06870>.

UniProt (2022q) *PLASMINOGEN ACTIVATOR RECEPTOR UROKINASE-P00749 (UROK\_HUMAN); PLAU*.

UniProt (2022r) *Protein C - P04070 ( PROC \_ HUMAN )*. Available at:  
<https://www.uniprot.org/uniprot/P04070>.

UniProt (2022s) *Protein S - P07225 ( PROSI \_ HUMAN )*. Available at:  
<https://www.uniprot.org/uniprot/P07225>.

UniProt (2022w) *SERPINE1; PAI-1*. Available at:  
<https://www.uniprot.org/uniprot/P05121>.

UniProt (2022y) *Thrombomodulin*.

[Vandooren](#), J and Itoh, Y (2021) ‘Alpha-2-Macroglobulin in Inflammation, Immunity and Infections’ [Front Immunol](#). 2021; 12: 803244. 2021 Dec 14. doi: [10.3389/fimmu.2021.803244](https://doi.org/10.3389/fimmu.2021.803244).

[Varga](#) et al., ‘Endothelial cell infection and endotheliitis in COVID-19’ *Lancet*, 2020. May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.

[vonMeijenfeldt](#), FA *et al.* (2022) ‘Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al’ *J Thromb Haemost*, 2022 Jan;20(1):267-269. doi: 10.1111/jth.15580.

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., *et al.* (2020). ‘Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China’, *JAMA*, 323(11), 1061–1069.  
<https://doi.org/10.1001/jama.2020.1585>

Wang, I. E., Cooper, G., & Mousa, S. A. (2021). ‘Diagnostic Approaches for COVID-19 and Its Associated Complications’, *Diagnostics (Basel, Switzerland)*, 11(11), 2071. <https://doi.org/10.3390/diagnostics11112071>.

- [Ward, SE, O'Sullivan, JM, O'Donnell, JS](#) ‘ The relationship between ABO blood group, von Willebrand factor, and primary hemostasis’ *Blood*, 2020 Dec 17;136(25):2864-2874. doi: 10.1182/blood.2020005843
- Wen, H., Tipih, T., Makoah, N.A., Vermeulen, J.G., Goedhals, D., *et al.* (2021). ‘Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis’, *mBio*, 12(1), pp. e03647-20. doi: 10.1128/mBio.03647-20.
- Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A, *et al.* (2020). Autopsy findings and venous thromboembolism in patients with COVID-19. *Ann Intern Med.* 173(4):268-277.
- Won, T., Wood, M.K., Hughes, D.M., Talor, M.V., Ma, Z. *et al.* (2022). ‘Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs’, *EBioMedicine*, 75, 103812. doi: 10.1016/j.ebiom.2022.103812.
- World Health Organization. (2020). Novel Coronavirus (2019-nCoV) Situation Report - 54 [Internet]. WHO. Available from: [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200314-sitrep-54-covid-19.pdf?sfvrsn=dcd46351\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200314-sitrep-54-covid-19.pdf?sfvrsn=dcd46351_2).
- Xiao, F. *et al.* (2020) ‘Evidence for Gastrointestinal Infection of SARS-CoV-2’, *Gastroenterology*, 158(1), pp. 1831–1833.
- Xu, X. *et al.* (2020) ‘Evolution Of The Novel Coronavirus From The Ongoing Wuhan Outbreak And Modeling Of Its Spike Protein For Risk Of Human Transmission’, *Science China Life Sciences*, 63(3), pp. 457–460.
- Yan, R, *et al.* (2020), ‘Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2’ [Science](#). 2020 Mar 27; 367(6485): 1444–1448. doi: [10.1126/science.abb2762](https://doi.org/10.1126/science.abb2762).
- Yao, Y., Wang, H., & Liu, Z. (2020). ‘Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases’, *Clinical and experimental allergy : journal*

*of the British Society for Allergy and Clinical Immunology*, 50(12), pp. 1313–1324. <https://doi.org/10.1111/cea.13746>

Yao, Y. *et al.* (2020) ‘D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study’, *Journal of Intensive Care*. *Journal of Intensive Care*, 8(1), pp. 1–11. doi: 10.1186/s40560-020-00466-z.

Ye, Y *et al* (2017) ‘Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases’ *Int J Mol Sci*. 2017 Jul 29;18(8):1651. doi: 10.3390/ijms18081651.

Yegorov, S. *et al.* (2021) ‘Epidemiology, clinical characteristics, and virologic features of COVID-19 patients in Kazakhstan: A nation-wide retrospective cohort study’, *Lancet Reg Health Eur*, 4:100096. doi: 10.1016/j.lanepe.2021.100096.

Yuki, K., Fujiogi, M. and Koutsogiannaki, S. (2020) ‘Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information ’, (January).

Zhang, H. *et al.* (2020) ‘Angiotensin-converting enzyme 2 (ACE2) as a SARS- CoV-2 receptor: molecular mechanisms and potential therapeutic target’, *Intensive Care Medicine*. Springer Berlin Heidelberg, 46(4), pp. 586–590. doi: 10.1007/s00134-020-05985-9.

Zhang, J. J., Dong, X., Cao, Y. Y., Yuan, Y. D., Yang, Y. B., *et al.* (2020). ‘Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.’ *Allergy*, 75(7), 1730–1741. <https://doi.org/10.1111/all.14238>

Zhang, Y. *et al.* (2020) ‘Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients’, *Journal of Thrombosis and Thrombolysis*. Springer US, 50(3), pp. 580–586. doi:10.1007/s11239-020-02182-9.



Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet*. 395(10229):1054-1062.

Zhu, N. *et al.* (2020) 'A Novel Coronavirus from Patients with Pneumonia in China, 2019', *New England Journal of Medicine*, 382(8), pp. 727–733. doi: 10.1056/nejmoa2001017.

